Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the ovarian cancer drug market will more than triple over the next decade, increasing from $460 million in 2011 to $1.4 billion in 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
40508
The ovarian cancer drug market will more than triple over the next decade, increasing from $460 million in 2011 to $1.4 billion in 2021
103114
Shortages of prescription drugs occurring more frequently
175596
Compugen discovers cancer treatment target
51435
Generic medicines could offer substantial saving
94470
Thousands of cancer patients to benefit from new drug
98213
By 2019, the acute gout drug market will triple in size while the chronic gout drug market will reach $1.83 billion
174826
Hypercholesterolemia partnering 2007-2012
147426
More and more patients survive cancer
60131
Adometry raises $8M more
36307
Cancer treatment enters 'very exciting' era
136418
Roche to strengthen global leadership position in oncology, to expand therapeutic areas
137890
Anti-cancer drug for women weakens bones
111953
Marketing budgets rise
100995
Statins at time of surgery may improve survival in ovarian cancer
19593
Drug plans not sustainable
79082
Pharmaceutical industry faces collapse
28006
Marie Curie Cancer Care challenges businesses to test their wits